Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Evaluation of Macular Vascular Abnormalities Identified by Optical Coherence Tomography Angiography in Sickle Cell Disease
source: American Journal of Ophthalmology
year: 2017
authors: Han IC, Tadarati M, Pacheco KD, Scott AW
summary/abstract:PURPOSE:
To evaluate macular vascular flow abnormalities identified by optical coherence tomography angiography (OCT-A) in patients with various sickle cell genotypes.
DESIGN:
Prospective, observational case series.
METHODS:
This is a single-institution case series of adult patients with various sickle cell genotypes. All patients underwent macular OCT-A (Avanti RTVue XR). Images were analyzed qualitatively for areas of flow loss and quantitatively for measures of foveal avascular area, parafoveal flow, and vascular density. The findings were compared by sickle cell genotype and retinopathy stage and correlated to retinal thickness and visual acuity.
RESULTS:
OCT-A scans of 82 eyes from 46 patients (60.9% female, mean age 33.5 years) were included. Sickle cell genotypes included 27 patients with hemoglobin SS (58.7%), 14 SC (30.4%), 4 beta-thalassemia (8.7%), and 1 sickle trait (2.2%). Discrete areas of flow loss were noted in 37.8% (31/82) of eyes overall and were common in both SS (40.0%, 20/50 eyes) and SC (41.7%, 10/24 eyes). Flow loss was more extensive in the temporal and nasal parafoveal subfields of the deep plexus with sickle SC or proliferative retinopathy. Retinal thickness measurements correlated with vascular density of the fovea, parafovea, and temporal and superior subfields. Visual acuity correlated with foveal avascular zone area and parafoveal vascular density in the superficial and deep plexi.
CONCLUSIONS:
Areas of abnormal macular vascular flow are common in patients with various sickle cell genotypes. These areas may be seen at any retinopathy stage but may be more extensive with sickle SC or proliferative retinopathy.
DOI: 10.1016/j.ajo.2017.02.007
read more full text
+myBinderRelated Content
-
Prostacyclin-analog therapy in sickle cell pulmonary hypertensionSickle cell disease (SCD) is associated ...
-
Outcome of severe vaso occlusive crisis in sickle cell disease adults admitted to referral centers in Africa and Eur...Introduction: Vaso-Occlusive Crisis (VOC...
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
Vaso-Occlusive Pain Linked to Menstruation in Some Patients, Study FindsAcute vaso-occlusive pain is associated ...
-
Sickle cell trait may not increase the risk of deathPeople who carry a gene for sickle cell ...
-
Grant Recipient Uses Mobile Device Observation in Sickle Cell Pain StudyTechnology takes center stage in a new...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.